Breaking News

Particle Sciences, Actavis In Generic Drug Pact

April 2, 2014

Particle to provide design, formulation and cGMP supplies

Particle Sciences has entered into an exclusive agreement with Actavis plc to develop an undisclosed complex generic product. Particle Sciences is responsible for design, formulation and cGMP supplies, and will receive undisclosed milestone and revenue- based payments. Actavis will be responsible for clinical testing, regulatory filings and marketing. 
 
"We have worked with Actavis on a number of projects in the past," said Mark Mitchnick, Particle Sciences' chief executive officer. "This latest one leverages several of Particle Sciences core skillsets focused on sterile products with challenging formulation targets." 
 
"Over the past several years Particle Sciences has intentionally moved towards closer relationships with our clients by structuring our interactions to best align our respective goals," Mitchnick added. "This latest venture is a great example, and we are very pleased to have Actavis as our co-developer and marketer."

Related Contract Manufacturing:

Related Packaging:

Related Compliance:

blog comments powered by Disqus
  • Solid Dispersions

    Solid Dispersions

    Robert Harris, Juniper Pharma Services||April 5, 2016
    A universal formulation strategy for poorly soluble drugs?

  • Major Regulatory Changes in China to Impact Western Drug Developers

    Major Regulatory Changes in China to Impact Western Drug Developers

    David Deere, PaizaBio||January 28, 2016
    PaizaBio reports on drug development and manufacturing strategies

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.